Having proposed the decision tree for the personalized chemotherapy and targeted therapy guidance, we next set out to determine whether comparing S-overrepresented and NS-overrepresented proteomes could distinguish sensitive GC patients from non-sensitive GC patients in response to DOS therapy, XELOX therapy, anti-HER2 therapy or combined with chemotherapies (Fig. 6a). Here, ERBB2 is linked to gastric cancer.